How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,484 results for

Vitiligo

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Vitiligo-like depigmentations as first sign of melanoma; a retrospective case series from a tertiary vitiligo centre. (PubMed)

Vitiligo-like depigmentations as first sign of melanoma; a retrospective case series from a tertiary vitiligo centre. 27273338 2017 05 18 2018 12 02 1365-2133 176 2 2017 02 The British journal of dermatology Br. J. Dermatol. Vitiligo-like depigmentations as the first sign of melanoma: a retrospective case series from a tertiary vitiligo centre. 503-506 10.1111/bjd.14790 Teulings H E HE Department of Dermatology and the Netherlands Institute for Pigment Disorders (SNIP), Academic Medical Center (...) Dermatol Ges. 2008 Dec;6(12):1053-9 18479500 Humans Hypopigmentation Melanoma Research Design Retrospective Studies Skin Neoplasms Vitiligo 2016 6 9 6 0 2017 5 19 6 0 2016 6 9 6 0 ppublish 27273338 10.1111/bjd.14790

2016 British Journal of Dermatology

22. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. (PubMed)

New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. The development of vitiligo during treatment with biological agents is an unusual event and only a few isolated cases have been reported.To describe the clinical characteristics and evolution of patients developing new-onset vitiligo following initiation of a biological agent for chronic inflammatory disease; and also to report the clinical course of pre-existing (...) vitiligo under biological therapy.This nationwide multicentre, retrospective study, carried out between July 2013 and January 2015, describes the characteristics of a large series of 18 patients (psoriasis N = 8, inflammatory rheumatic diseases N = 8, ulcerative colitis N = 1, uveitis N = 1) who developed new-onset vitiligo while receiving a biological agent.TNFα inhibitors were the most common biological agent involved (13/18) while anti-IL-12/23 and anti-IL-17 agents or abatacept were less common (4

Full Text available with Trip Pro

2016 Journal of the European Academy of Dermatology and Venereology

23. Increased Expression of CXCR3 and its Ligands in Vitiligo Patients and CXCL10 as a Potential Clinical Marker for Vitiligo. (PubMed)

Increased Expression of CXCR3 and its Ligands in Vitiligo Patients and CXCL10 as a Potential Clinical Marker for Vitiligo. Vitiligo is a skin disorder characterized by loss of melanocytes from the epidermis. A recent study reported that CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo, but there is very limited clinical data regarding this issue and little is known about the dynamic changes or correlations with disease severity (...) of these chemokines throughout the disease course.To present clinical data that supports and identifies the pathway of CXCR3 and its ligands in T-lymphocytic cell recruitment in vitiligo.Cytometric bead array, flow cytometry, quantitative real-time polymerase chain reaction and immunohistology were used to examine their systemic and local expression in 80 patients with vitiligo and 40 controls.We showed that serum CXCL9 and CXCL10 were significantly elevated in patients with vitiligo and were higher in patients

2016 British Journal of Dermatology

24. Association of class I and II HLA alleles and haplotypes with susceptibility to vitiligo: a study of patients with vitiligo from southeast Brazil. (PubMed)

Association of class I and II HLA alleles and haplotypes with susceptibility to vitiligo: a study of patients with vitiligo from southeast Brazil. The association of vitiligo with the HLA complex has been previously described in various populations worldwide. However, until now, no similar study has been conducted in Brazil. The aim of this study was to determine the association of HLA alleles with vitiligo in the population of southeast Brazil.DNA samples from 116 patients with vitiligo (...) = 0.3120, OR = 22.43, 95% CI = 1.12-449.46) and HLA-DQB1*06 (P = 0.0207, Pc = 0.1035, OR = 0.28, 95% CI = 0.10-0.81) were associated with both localized and generalized vitiligo. The haplotype analysis revealed that A*02-B*51-C*15-DRB1*07-DQB1*02 (P = 0.0113), A*02-B*15-C*07-DRB1*13-DQB1*06 (P = 0.0340), and A*29-B*44-C*16-DRB1*07-DQB1*02 (P = 0.0340) were associated with a predisposition to the disease.Our results show that HLA alleles and haplotypes may contribute to the pathogenesis of vitiligo

2016 International Journal of Dermatology

25. The changes of gene expression profiling between segmental vitiligo, generalized vitiligo and healthy individual. (PubMed)

The changes of gene expression profiling between segmental vitiligo, generalized vitiligo and healthy individual. Vitiligo is a common acquired depigmentation skin disease characterized by loss or dysfunction of melanocytes within the skin lesion, but its pathologenesis is far from lucid. The gene expression profiling of segmental vitiligo (SV) and generalized vitiligo (GV) need further investigation.To better understanding the common and distinct factors, especially in the view of gene (...) expression profile, which were involved in the diseases development and maintenance of segmental vitiligo (SV) and generalized vitiligo (GV).Peripheral bloods were collected from SV, GV and healthy individual (HI), followed by leukocytes separation and total RNA extraction. The high-throughput whole genome expression microarrays were used to assay the gene expression profiles between HI, SV and GV. Bioinformatics tools were employed to annotated the biological function of differently expressed genes

2016 Journal of dermatological science

26. Genetic Susceptibility to Vitiligo: GWAS Approaches for Identifying Vitiligo Susceptibility Genes and Loci (PubMed)

Genetic Susceptibility to Vitiligo: GWAS Approaches for Identifying Vitiligo Susceptibility Genes and Loci Vitiligo is an autoimmune disease with a strong genetic component, characterized by areas of depigmented skin resulting from loss of epidermal melanocytes. Genetic factors are known to play key roles in vitiligo through discoveries in association studies and family studies. Previously, vitiligo susceptibility genes were mainly revealed through linkage analysis and candidate gene studies (...) . Recently, our understanding of the genetic basis of vitiligo has been rapidly advancing through genome-wide association study (GWAS). More than 40 robust susceptible loci have been identified and confirmed to be associated with vitiligo by using GWAS. Most of these associated genes participate in important pathways involved in the pathogenesis of vitiligo. Many susceptible loci with unknown functions in the pathogenesis of vitiligo have also been identified, indicating that additional molecular

Full Text available with Trip Pro

2016 Frontiers in genetics

27. Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL) (PubMed)

Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL) Vitiligo is a multi-factorial pigmentary skin disorder. Recently, the importance of emotional and psychological issues is proposed in incidence, progression, relapse and remission of vitiligo. There are limited studies conducted in developing countries, which assess life quality of patients with vitiligo. The aim of this study was the application and evaluation of a disease (...) -specific quality of life index in Iranian patients, for the first time.This cross-sectional biphasic study was conducted on 25 patients as a pilot and another 173 patients as the main study group, in Razi Hospital, Tehran, Iran, 2013-2014. Persian version of Vitiligo Quality of Life index (VitiQoL) was developed with backward-forward method. Based on the pilot study, the validity and reliability were assessed. The Vitiligo Area and Score Index (VASI), VitiQoL, and their relationship, demographic

Full Text available with Trip Pro

2016 Health and quality of life outcomes

28. Comparison of efficacy of cold trypsinization versus warm trypsinization in preparation of autologous noncultured epidermal cell suspension for treatment of stable vitiligo. (PubMed)

Comparison of efficacy of cold trypsinization versus warm trypsinization in preparation of autologous noncultured epidermal cell suspension for treatment of stable vitiligo. 30768811 2019 03 12 1468-3083 2019 Feb 15 Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Comparison of efficacy of cold trypsinization versus warm trypsinization in preparation of autologous non-cultured epidermal cell suspension for treatment of stable vitiligo. 10.1111

2019 Journal of the European Academy of Dermatology and Venereology

29. Cross cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs). (PubMed)

Cross cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs). there is a lack for short forms questionnaire evaluating the burden of Vitiligo according to skin phototype OBJECTIVE: To develop and validate a 12-item short-form of the Vitiligo Impact Patient Scale (VIPs) that takes into account skin phototype.Multicentric, prospective, cross-sectionnal study conducted in France (Créteil and Bordeaux) and the US (Worcester, Massachusetts and Dallas, Texas).In total, 891

2019 Journal of American Academy of Dermatology

30. Assessment of telomerase activity in nonsegmental vitiligo tissue: a pilot study. (PubMed)

Assessment of telomerase activity in nonsegmental vitiligo tissue: a pilot study. Vitiligo is characterized by loss of melanocytes; therefore, an increased risk of photoageing and cancer are expected. However, a low incidence of cancer and sun damage in vitiliginous skin has been reported. Telomerase is a specialized cellular enzyme catalysing the synthesis of telomeres, and an increased level of the telomerase activity has been highlighted in most of human cancer cells and cancer cell lines.To (...) assess relative telomerase activity (RTA) among patients with nonsegmental vitiligo.In this case-control study, skin biopsy specimens were taken from 20 patients (one from lesional and another from nonlesional skin) and from sun-protected skin from 10 healthy age-, sex- and skin phototype-matched healthy controls. PCR ELISA was performed for assessment of RTA.RTA in lesional skin biopsies from patients with nonsegmental vitiligo was significantly decreased compared with nonlesional skin and healthy

2019 Clinical & Experimental Dermatology

31. Mechanisms of repigmentation induced by photobiomodulation therapy in vitiligo. (PubMed)

Mechanisms of repigmentation induced by photobiomodulation therapy in vitiligo. Photobiomodulation (PBM) therapy is based on the exposure of biological tissues to low-level laser light (coherent light) or light-emitting diodes (LEDs; noncoherent light), leading to the modulation of cellular functions, such as proliferation and migration, which result in tissue regeneration. PBM therapy has important clinical applications in regenerative medicine. Vitiligo is an acquired depigmentary disorder (...) resulting from disappearance of functional melanocytes in the involved skin. Vitiligo repigmentation depends on available melanocytes derived from (a) melanocyte stem cells located in the bulge area of hair follicles and (b) the epidermis at the lesional borders, which contains a pool of functional melanocytes. Since follicular melanoblasts (MBs) are derived from the melanocyte stem cells residing at the bulge area of hair follicle, the process of vitiligo repigmentation presents a research model

2019 Experimental Dermatology

32. Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. (PubMed)

Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. The understanding of the immune mechanisms of vitiligo has profoundly improved over the past years. The recent discovery of a new population of antigen-experienced memory T cells called resident memory T cells (TRM ) has changed the concept of immune surveillance in peripheral tissue as skin, and the presence of melanocyte-specific TRM (...) is clearly demonstrated in vitiligo, a disease that could be now seen such as a memory skin disease. This review summarizes the recent knowledge on skin TRM and their role in vitiligo. Future management or therapies for this disease will have the goal to block their migration/differentiation, to dampen their activation and/or their accumulation in the vitiligo skin to prevent flare-up or to promote repigmentation.© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Full Text available with Trip Pro

2019 Experimental Dermatology

33. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. (PubMed)

Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Vitiligo-like depigmentation (VLD) is a characteristic cutaneous event described in patients with metastatic malignant melanoma receiving treatment with immune checkpoint inhibitors. We report the onset of VLD in three patients with other cancer types (cholangiocarcinoma, renal cell carcinoma and squamous cell carcinoma) following treatment with immunotherapy (combination

2019 Clinical & Experimental Dermatology

34. Efficacy of Transplantation of Combination of Noncultured Dermal and Epidermal Cell Suspension vs Epidermal Cell Suspension Alone in Vitiligo: A Randomized Clinical Trial. (PubMed)

Efficacy of Transplantation of Combination of Noncultured Dermal and Epidermal Cell Suspension vs Epidermal Cell Suspension Alone in Vitiligo: A Randomized Clinical Trial. Surgical interventions, notably noncultured epidermal suspension (NCES), are the next line of treatment in patients with vitiligo who fail to respond to medical therapy. Noncultured epidermal suspension is usually performed in patients with vitiligo with duration of clinical stability (DS) of 12 months or longer because DS (...) is a vital parameter in determining outcome of NCES. In this pilot study, we planned to assess the efficacy of a novel combination of noncultured epidermal cell suspension and noncultured dermal cell suspension (NCES and NDCS) in patients with vitiligo with shorter DS (3-6 months).To compare the efficacy of transplantation of NCES and NDCS vs NCES alone in patients with vitiligo with DS of 3 to 6 months.A single-center randomized clinical trial including 40 patients with focal, segmental, or generalized

2019 JAMA dermatology (Chicago, Ill.)

35. Efficacy of NB-UVB, microneedling with triamcinolone acetonide, and a combination of both modalities in the treatment of vitiligo: A comparative study. (PubMed)

Efficacy of NB-UVB, microneedling with triamcinolone acetonide, and a combination of both modalities in the treatment of vitiligo: A comparative study. 29291952 2019 01 03 2019 01 03 1097-6787 79 2 2018 Aug Journal of the American Academy of Dermatology J. Am. Acad. Dermatol. Efficacy of NB-UVB, microneedling with triamcinolone acetonide, and a combination of both modalities in the treatment of vitiligo: A comparative study. 365-367 S0190-9622(17)32894-3 10.1016/j.jaad.2017.12.054 Elshafy (...) 29 United States J Am Acad Dermatol 7907132 0190-9622 0 Anti-Inflammatory Agents F446C597KA Triamcinolone Acetonide IM Adolescent Adult Anti-Inflammatory Agents therapeutic use Combined Modality Therapy Female Humans Male Middle Aged Needles Patient Satisfaction Punctures Triamcinolone Acetonide therapeutic use Ultraviolet Therapy Vitiligo drug therapy radiotherapy therapy Young Adult 2017 08 21 2017 11 07 2017 12 13 2018 1 3 6 0 2019 1 4 6 0 2018 1 3 6 0 ppublish 29291952 S0190-9622(17)32894-3

2019 Journal of the American Academy of Dermatology

36. Six-year follow-up of vitiligo patients successfully treated with autologous non-cultured melanocyte-keratinocyte transplantation. (PubMed)

Six-year follow-up of vitiligo patients successfully treated with autologous non-cultured melanocyte-keratinocyte transplantation. Although autologous non-cultured melanocyte-keratinocyte transplantation is a treatment option for stable vitiligo, there is lack of long-term maintenance data for this specific treatment.To search for factors associated with long-term maintenance of patients with stable vitiligo successfully treated with melanocyte-keratinocyte transplantation.This was a single (...) -centre retrospective study including stable vitiligo patients who underwent successful melanocyte-keratinocyte transplantation in the National Center for Vitiligo, Riyadh, Saudi Arabia, between 1 January 2004 and 30 June 2015. Cox proportional hazard model was used to estimate factors associated with relapse at 6 years of followup. Co-variates included, gender, type of vitiligo, age at vitiligo onset, age at surgical procedure, disease duration, disease stability, affected body surface area, treated

2019 Journal of the European Academy of Dermatology and Venereology

37. Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study. (PubMed)

Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study. Recent studies indicated that the autoimmunity of vitiligo exerts effects on cells other than melanocytes, which confer reduced risks of both melanoma and nonmelanoma skin cancers in patients with vitiligo. However, the risk of internal malignancy in patients with vitiligo has not been elucidated.We conducted a population-based retrospective cohort study using data from (...) the Korean National Health Insurance claims database obtained from January 2007 to December 2016. All patients age 20 years or older with vitiligo who had at least two contacts with a physician from 2009 to 2016, during which a principal diagnosis was made, were identified (vitiligo group). Controls were randomly selected (two per patient with vitiligo) after frequency matching with the vitiligo group for age and sex during the same period (control group).A total of 101,078 patients with vitiligo

2019 Journal of Clinical Oncology

38. The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial. (PubMed)

The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial. Vitiligo is a chronic skin disorder presenting with depigmentation, the pathogenesis of which is complex but the autoimmune theory is now preferred. Multiple immunologic processes, including stimulation of the T-helper (Th)1 response, formation (...) of autoreactive melanocyte-specific CD8+ T lymphocytes, a decrease in the blood concentration of T regulatory (Treg) cells, and an increase in interleukin (IL)-17 and interferon (IFN) concentration, have been shown to contribute to vitiligo progression and maintenance. The aim of this study is to evaluate the influence of simvastatin and atorvastatin on vitiligous lesions in patients with nonsegmental vitiligo (NSV). According to available data, statins act through several immunological pathways, potentially

Full Text available with Trip Pro

2019 Trials

39. Comparison of 311-nm Titanium:Sapphire laser and 308-nm excimer laser treatment for vitiligo: A randomized controlled non-inferiority trial. (PubMed)

Comparison of 311-nm Titanium:Sapphire laser and 308-nm excimer laser treatment for vitiligo: A randomized controlled non-inferiority trial. The 308-nm excimer laser (EL) has been widely used for localized vitiligo. The recently developed Titanium:Sapphire laser, emits a wavelength of 311 nm, would be expected to be as effective as excimer laser in treatment of vitiligo but few controlled trials have been reported. We sought to compare the efficacy and safety of the TSL and EL as vitiligo (...) treatments.A randomized controlled non-inferiority trial based on split-body was conducted. Patients with stable vitiligo between June 2016 and May 2017 were enrolled. Paired symmetrical vitiligo lesions were randomized to either the EL or TSL treatment group, and treated with a 308-nm EL or a 311-nm TSL twice weekly for 12 weeks. The extent of repigmentation was assessed every 4 weeks, and the non-inferiority margin was set to 10%. We also recorded any adverse events.Seventy-four paired lesions in 21

2019 Lasers in surgery and medicine

40. Comprehensive lipidomic, metabolomic and proteomic profiling reveals the role of immune system in vitiligo. (PubMed)

Comprehensive lipidomic, metabolomic and proteomic profiling reveals the role of immune system in vitiligo. Vitiligo is a common depigmentation disorder resulting from destruction of melanocytes, with both genetic and environmental influences. Although genomic analyses have been performed to investigate the pathogenesis of vitiligo, the lipidomics, metabolomics and proteomics of serum have not been reported and the role of small molecules and serum proteins in vitiligo remains unknown.To study (...) the metabolite and protein profiles in vitiligo and healthy controls, plasma samples from 60 participants (29 vitiligo and 31 healthy) were analyzed. Untargeted lipidomics, metabolomics and iTRAQ-based proteomics were performed using ultra-performance liquid chromatography-tandem mass spectrometry. In addition, to validate differentially expressed metabolites in vitiligo patients, plasma enzyme-linked immunosorbent assay was performed.We identified differential expression of several metabolites and proteins

2019 Clinical & Experimental Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>